Lifileucel TIL therapy (11, 13), regorafenib (12), ERK5 inhibitors (14, 15), and targeting CD73 (16) represent other promising avenues to enhance treatment efficacy and manage resistance in advanced melanoma. This evidence concerns the gene NT5E and melanoma.